Peijia Medical (HKG:9996) completed the first patient treatment of the first-in-man clinical trial of ReachTactile robotic-assisted transcatheter aortic valve replacement (TAVR) system on April 2, an April 6 filing with the Hong Kong bourse said.
The procedure was performed by Professor Yan Wang and his team in Xiamen Cardiovascular Hospital of Xiamen University, during which the system was used to implant a TaurusElite(r) transcatheter aortic valve in a patient with severe aortic stenosis.
ReachTactile, the medical device manufacturer's internally developed robotic-assisted TAVR system, offers an innovative solution for TAVR therapy.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。